Filippo Ceccato1,2, Laura Lizzul3, Mattia Barbot3, Carla Scaroni3. 1. Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, Italy. filippo.ceccato@unipd.it. 2. Department of Neurosciences DNS, University of Padova, Padova, Italy. filippo.ceccato@unipd.it. 3. Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, Italy.
Abstract
BACKGROUND AND AIM: A close relationship between adiposity and increased cortisol levels is well established in patients with endogenous hypercortisolism. Nevertheless, hypothalamic-pituitary-adrenal (HPA) axis regulation in overweight subjects is still a matter of concern. We studied free cortisol (urinary free cortisol, UFC and late night salivary cortisol, LNSC), pituitary feedback (serum cortisol after 1 mg dexamethasone suppression test, 1 mg DST) and peripheral cortisol metabolism (urinary cortisol to cortisone ratio, F/Eratio) in a large series of overweight subjects without Cushing's Syndrome. MATERIALS AND METHODS: We considered 234 patients divided in 5 BMI classes, matched for age and gender (BMI ≤ 25 kg/m2n = 38; 25-30 n = 58; 30-35 n = 52; 35-40 n = 52; >40 n = 34). UFC, LNSC and urinary F/Eratio were assessed with LC-MS. RESULTS: We collected 183 LNSC, 176 UFC, 152 1 mg DST and 64 F/Eratio tests. UFC levels were higher in lean subjects, and they decreased according to the BMI classes (p = 0.022). Non-suppressed cortisol levels (>50 nmol/L) after 1 mg DST were observed especially in patients with normal weight or mild obesity. Patients with BMI ≥ 35 kg/m2 revealed a reduced F/Eratio (0.39 vs. 0.61, p = 0.006). The specificity of tests (false positive results) was higher considering 1 mg DST or UFC in obese patients, on the contrary impaired cortisol rhythm (LNSC above normality) was observed in 47 subjects, irrespective of weight. CONCLUSIONS: Overweight and obese subjects are characterised by an original regulation of HPA axis (reduced UFC levels, increased suppression after 1 mg DST) and peripheral cortisol metabolism (reduced F/Eratio), suggesting an effort to counteract hypercortisolism.
BACKGROUND AND AIM: A close relationship between adiposity and increased cortisol levels is well established in patients with endogenous hypercortisolism. Nevertheless, hypothalamic-pituitary-adrenal (HPA) axis regulation in overweight subjects is still a matter of concern. We studied free cortisol (urinary free cortisol, UFC and late night salivary cortisol, LNSC), pituitary feedback (serum cortisol after 1 mg dexamethasone suppression test, 1 mg DST) and peripheral cortisol metabolism (urinary cortisol to cortisone ratio, F/Eratio) in a large series of overweight subjects without Cushing's Syndrome. MATERIALS AND METHODS: We considered 234 patients divided in 5 BMI classes, matched for age and gender (BMI ≤ 25 kg/m2n = 38; 25-30 n = 58; 30-35 n = 52; 35-40 n = 52; >40 n = 34). UFC, LNSC and urinary F/Eratio were assessed with LC-MS. RESULTS: We collected 183 LNSC, 176 UFC, 152 1 mg DST and 64 F/Eratio tests. UFC levels were higher in lean subjects, and they decreased according to the BMI classes (p = 0.022). Non-suppressed cortisol levels (>50 nmol/L) after 1 mg DST were observed especially in patients with normal weight or mild obesity. Patients with BMI ≥ 35 kg/m2 revealed a reduced F/Eratio (0.39 vs. 0.61, p = 0.006). The specificity of tests (false positive results) was higher considering 1 mg DST or UFC in obesepatients, on the contrary impaired cortisol rhythm (LNSC above normality) was observed in 47 subjects, irrespective of weight. CONCLUSIONS: Overweight and obese subjects are characterised by an original regulation of HPA axis (reduced UFC levels, increased suppression after 1 mg DST) and peripheral cortisol metabolism (reduced F/Eratio), suggesting an effort to counteract hypercortisolism.
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: Mohamed B Elamin; M Hassan Murad; Rebecca Mullan; Dana Erickson; Katherine Harris; Sarah Nadeem; Robert Ennis; Patricia J Erwin; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: E Rask; T Olsson; S Söderberg; R Andrew; D E Livingstone; O Johnson; B R Walker Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Angela C Incollingo Rodriguez; Elissa S Epel; Megan L White; Erin C Standen; Jonathan R Seckl; A Janet Tomiyama Journal: Psychoneuroendocrinology Date: 2015-08-21 Impact factor: 4.905
Authors: Renato Pasquali; Bruno Ambrosi; Decio Armanini; Francesco Cavagnini; Ettore Degli Uberti; Graziano Del Rio; Giovanni de Pergola; Mauro Maccario; Franco Mantero; Mario Marugo; Carlo Maria Rotella; Roberto Vettor Journal: J Clin Endocrinol Metab Date: 2002-01 Impact factor: 5.958
Authors: Eva Rask; Brian R Walker; Stefan Söderberg; Dawn E W Livingstone; Mats Eliasson; Owe Johnson; Ruth Andrew; Tommy Olsson Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958
Authors: G Spaggiari; M Setti; S Tagliavini; L Roli; M C De Santis; T Trenti; V Rochira; D Santi Journal: J Endocrinol Invest Date: 2020-10-29 Impact factor: 4.256